Veru Inc. (VERU)
VERU moved a median of -0.47% 30 minutes after news, and -0.46% by the close. How VERU actually reacts to news — the realized, point-in-time move the market made, measured across 230 labeled events over the last three years with zero look-ahead.
VERU’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 223 |
| 30-min | -0.47% | 43% | 228 |
| 60-min | -0.39% | 42% | 228 |
| to close | -0.46% | 46% | 222 |
| Middle 50% of VERU reactions | -3.01% to +1.24% |
|---|---|
| Median reaction (30-min) | -0.47% |
| Measured reactions | 230 |
Half of all Veru Inc. news events land between -3.01% and +1.24% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VERU moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VERU's baseline. Nothing else.
Recent VERU events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K VERU INC. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -4.69% | -6.86% | |
| Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial | Press release | GlobeNewswire | -4.69% | -6.86% | |
| Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | +1.48% | +1.85% | |
| Form 10-Q VERU INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +10.20% | — | |
| Form 8-K VERU INC. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | Press release | GlobeNewswire | — | — | |
| Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss | Press release | GlobeNewswire | +0.44% | +3.04% | |
| Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th | Press release | GlobeNewswire | -2.59% | -2.59% | |
| Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference | Press release | GlobeNewswire | +0.68% | +0.45% | |
| Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | Press release | GlobeNewswire | -1.71% | -2.56% | |
| Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day | Press release | GlobeNewswire | +0.00% | +1.77% | |
| Form 8-K VERU INC. For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | -9.03% | -5.35% | |
| Form 8-K VERU INC. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -1.61% | +94.04% | |
| Form 10-Q VERU INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.49% | -1.31% | |
| Form 8-K VERU INC. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -3.49% | -1.31% | |
| Form S-8 VERU INC. | SEC filing · Form S-8 | SEC EDGAR | -3.49% | -1.31% | |
| Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | Press release | GlobeNewswire | -3.49% | -1.31% | |
| Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th | Press release | GlobeNewswire | -0.45% | +0.00% | |
| Form EFFECT VERU INC. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +1.65% | |
| Form S-3 VERU INC. | SEC filing · Form S-3 | SEC EDGAR | +2.82% | +2.82% | |
| Form 8-K VERU INC. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | +0.42% | |
| Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | Press release | GlobeNewswire | +2.08% | +1.65% | |
| Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.00% | +4.18% | |
| Form 10-Q VERU INC. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.23% | -5.73% | |
| Form 8-K VERU INC. For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +6.90% | -0.86% | |
| Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress | Press release | GlobeNewswire | +6.90% | -0.86% | |
| Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th | Press release | GlobeNewswire | +1.40% | -2.32% | |
| Form DEF 14A VERU INC. For: Mar 12 | SEC filing · Form DEF | SEC EDGAR | -0.96% | +0.39% | |
| Form DEFA14A VERU INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.96% | +0.39% | |
| Form 10-K VERU INC. For: Sep 30 | SEC filing · Form 10-K | SEC EDGAR | -0.58% | -3.04% | |
| Form 8-K VERU INC. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +2.45% | -8.98% | |
| Form S-8 VERU INC. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.45% | |
| Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress | Press release | GlobeNewswire | +2.45% | -8.98% | |
| Veru to Report Fiscal Year 2025 Financial Results on December 17th | Press release | GlobeNewswire | +0.00% | -2.28% | |
| Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop | Press release | GlobeNewswire | +0.68% | -1.63% | |
| Veru to Present Two Abstracts at ObesityWeek 2025 | Press release | GlobeNewswire | +1.70% | +0.68% | |
| Form 8-K VERU INC. For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | +1.70% | +0.68% | |
| Veru Announces Pricing of $25 Million Public Offering | Press release | GlobeNewswire | +2.10% | +5.61% | |
| Veru Announces Proposed Public Offering | Press release | GlobeNewswire | +2.10% | +5.61% | |
| Form 8-K VERU INC. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | +3.61% | |
| Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity | Press release | GlobeNewswire | +0.81% | -4.26% | |
| Form 8-K VERU INC. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +2.12% | |
| Form 10-Q VERU INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.06% | — | |
| Form 8-K VERU INC. For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -0.76% | — | |
| Form 8-K VERU INC. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | — | |
| Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | Press release | GlobeNewswire | -0.70% | — | |
| Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology | Press release | Business Wire | -1.70% | — | |
| Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study | Press release | GlobeNewswire | -0.40% | -5.53% | |
| Veru Announces Reverse Stock Split | Press release | GlobeNewswire | -2.52% | -8.63% | |
| Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th | Press release | GlobeNewswire | -0.10% | -7.92% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VERU section they belong to.
Where else VERU is measured.
VERU earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Forward Pharma A/S - American Depositary Shares (FWP) | 230 | 0.00% | 37% |
| Opko Health, Inc. (OPK) | 230 | 0.00% | 51% |
| iRadimed Corporation (IRMD) | 229 | +0.10% | 55% |
| AEVI GENOMIC MEDICINE INC (GNMX) | 227 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Veru Inc.'s median reaction calculated?
Every labeled VERU news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 230 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of VERU's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VERU's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.